DECISION-Project’s Post

ZBP1-mediated apoptosis and inflammation exacerbate steatotic liver ischemia/reperfusion injury: https://buff.ly/45UFlEf Authors: Ran Liu, Huan Cao, Shuhua Zhang, Mao Cai, Tianhao Zou, Guoliang Wang, Di Zhang, Xueling Wang, Jianjun Xu, Shenghe Deng, Tongxi Li, Daichao Xu, Jinyang Gu #Transplantation

Did you know that FFPE (Formalin-Fixed Paraffin-Embedded) liver tissue blocks are pivotal in enhancing our comprehension of liver ailments? Here's why they matter: 1. Preservation: FFPE blocks ensure the long-term preservation of liver tissue, facilitating future analyses and providing researchers with an invaluable resource. 2. Insights into Diseases: They offer valuable insights into the molecular and histological changes occurring in liver diseases such as cirrhosis and hepatitis. 3. Therapeutic Development: Researchers utilize these blocks to develop and evaluate new therapies for liver diseases, potentially leading to life-saving treatments. 4. Personalized Medicine: They play a significant role in personalized medicine by enabling tailored treatment strategies based on an individual's specific liver condition. Whether you're a scientist, medical professional, or simply intrigued by medical progress, FFPE liver tissue blocks are an intriguing component of liver disease research. Let's continue to support the remarkable efforts in the field of liver health. Connect us at support@thebiospecimen.com or sales@thebiospecimen.com or visit www.thebiospecimen.com #LiverHealth #ResearchMatters #MedicalAdvancements #FFPEBlocks #Livercancer #freshfrozen #biosamples #biobank #researchanddevelopment

⚠ Kidney International Reports' July issue is out! Read the latest news in research, highlights from current literature, comprehensive reviews, and in-depth case studies. Read the editor's pick for this month: ➡️ Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial https://ow.ly/HcUX50SuwH9 ➡️ Advances of Iron and Ferroptosis in Diabetic Kidney Disease https://ow.ly/Z2Vv50SuwHf ➡️ Structures, Organization, and Delivery of Kidney Care to Children Living in Low-Resource Settings https://ow.ly/k4Bx50SuwHg ➡️ Exploring Potential Gender-Based Disparities in Referral for Transplant, Activation on the Waitlist and Kidney Transplantation in a Canadian Cohort https://ow.ly/ENou50SuwHh Grow professionally with the ISN. Access high-impact scientific and clinical research through our journals. Join/renew your ISN Membership ➡️ https://ow.ly/rboY50SuwH8 #ThisIsISN - Advancing kidney health worldwide. Together.

Today on Global Fatty Liver Day, it is inspiring to see how many stakeholders are making a difference in raising awareness about MASLD/MASH in their own way. I joined the specific field of fatty liver research in 2018 and never looked back. Inspired by Dr. Harrison and his partnership throughout the past 6 years, it has been an incredible journey. Rezdiffra crossing the finish line has helped bring even more hope and excitement to the field and to patients living with MASH. At Pinnacle Clinical Research our teams are dedicated to providing options for patients, making clinical trials more accessible, and raising the bar in terms of disease state awareness. Together we envision a future where MASH and all its phenotypes are treatable conditions and where screening for liver disease becomes the norm for those at risk. We envision a future where fatty liver centers of excellence don’t just exist at large academic institutions and where algorithms for treatment take ethnicity and genetic makeup into consideration. As we say at Pinnacle, “If you want to go fast, go alone. If you want to go far, go together.” #globalfattyliverday #masld #fattyliver #hepatology #clinicaltrials #awareness #prevention

Check out our recent commentary with @LAK674 @rob_elhumano @dhingra_ri5921 in @NatureComms describing DIAPH1-MFN2 interaction decreases the ER-mitochondrial distance and promotes cardiac injury following myocardial ischemia. https://lnkd.in/eRi_ZXji

📰 Extra, extra, read all about it! #KPMPNews article dropped today! Thrilled to share that KPMP is featured in the latest National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Director's Update, highlighting our patient-centered work in kidney disease research. Authored by Steven Winter, the update emphasizes patient engagement in advancing precision medicine. Key highlight: KPMP's creation of the most comprehensive "human kidney cell atlas" to date, enabling personalized treatments. Participants, like Emanuel Holley, and patient partners, such as Christy Stutzke, play a vital role in driving KPMP research forward. Read the full update to learn how we're revolutionizing kidney precision medicine. #KidneyPrecisionMedicineProject #PatientEngagement #NIDDK 🔗 https://lnkd.in/gbuYKAfx

𝗗𝗼 𝘆𝗼𝘂 𝗸𝗻𝗼𝘄 𝘄𝗵𝘆 𝗖𝗵𝗮𝗿𝗰𝗼𝘁’𝘀 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗶𝘀 𝗹𝗶𝗻𝗸𝗲𝗱 𝘁𝗼 𝗮𝗴𝗶𝗻𝗴, 𝗲𝘃𝗲𝗻 𝗶𝗻 𝗶𝘁𝘀 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗳𝗼𝗿𝗺𝘀? 🤔 Even when the disease has a genetic origin, symptoms only appear later in life due to the decline in our brain’s cell repair systems. Motor neurons are the most active nerve cells in the body. They are also the ones that age the fastest. As we age, the nervous system can no longer "contain" the pathology. The loss of motor neurons leads to a progressive loss of muscle control, especially in the respiratory muscles of patients. The first symptoms typically appear around the age of 50, and the disease's prognosis is severe, with half of the patients passing away within three years. Today, #ALS affects over 8,000 people in France and 500,000 worldwide. Except for an extremely rare genetic form, there is no curative treatment available. Thanks to the research of Alain PROCHIANTZ, co-founder of BrainEver, a rejuvenation mechanism specific to these motor neurons has been discovered through homeoproteins. This breakthrough could slow the progression of Charcot’s disease, as well as other degenerative diseases, such as Parkinson disease or glaucoma. We need your support this hypothesis during our clinical trials scheduled for 2025. Join the BrainEver journey via Tudigo 👉 https://lnkd.in/eaKk6_Kt #Research #Innovation #Health #Biotech #PrivateEquity

At OWL Metabolomics our expertise in #MASLD and #MASH drives our innovative approach, exemplified by our OWLiver Panel. OWLiver, a non-invasive diagnostic tool, leverages UHPLC-MS technology to analyze fasting blood samples and detect lipid biomarkers essential for liver health assessment. This innovative tool offers critical insights into liver health, aiding in the management of related metabolic disorders. We're excited to announce that OWLiver is now available in the United States through our partners, CIMA Sciences, LLC and Luxor Scientific.This expansion brings our revolutionary diagnostic tool closer to you, providing comprehensive liver health insights and enhancing patient care. Discover the impact of OWLiver and see how we're transforming liver health assessment with our pioneering non-invasive diagnostics. Step into the future of liver health with OWLiver at OWL Metabolomics. #LuxorScientific #CIMASciences #OWLMetabolomics #OWLIVER #LiverHealth #ActNowScreenToday #NASH #MASH #NAFLD #MASLD #LiverCommunity #PatientCare #LiverStrong #NoninvasiveTesting

Did you know that there's a genetic risk factor for heart attacks that is often overlooked? Lp(a) is a protein that can greatly increase heart attack chances when present in high levels in the blood. Check out this recent article featuring insights about Lp(a) from expert physicians, including VitalSolution-Cardiology's Chief Medical Officer, Dr. Bradley Serwer. #HeartHealth #KnowYourRisks #LpaAwareness

Did you know that there's a genetic risk factor for heart attacks that is often overlooked? Lp(a) is a protein that can greatly increase heart attack chances when present in high levels in the blood. Check out this recent article featuring insights about Lp(a) from expert physicians, including VitalSolution-Cardiology's Chief Medical Officer, Dr. Bradley Serwer. #HeartHealth #KnowYourRisks #LpaAwareness